CD274 and adenocarcinoma: Based on this evidence, ASCO guidelines recommend nivolumab plus chemotherapy for gastric, GEJ, or esophageal adenocarcinoma with PD-L1 CPS ≥ 5; pembrolizumab plus chemotherapy for CPS ≥ 10 in adenocarcinoma or ESCC; and either nivolumab plus chemotherapy or nivolumab plus ipilimumab for ESCC with TPS ≥ 1 [60].